File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

TitleAn In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models
Authors
Issue Date2013
PublisherSAGE Journals. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510
Citation
Integrative Cancer Therapies, 2013, v. 12, p. 336-346 How to Cite?
AbstractObjectives. Erxian Decoction (EXD) is a well-documented Chinese medicinal formulation, which has been clinically applied for years for relieving menopausal syndromes by modulating hormonal levels indicating that EXD might also be effective in treating hormone-related tumors. This study aimed to differentially investigate the efficacy of EXD and its antimetastatic property on human ovarian cancer cells, OVCA429. Methods. The efficacy and cell cycle progression of EXD on OVCA429 cells was determined by MTT assay and flow cytometry, respectively. The modulated expression of metastatic markers by EXD in OVCA429 cells and xenografts was evaluated at transcriptional and translational levels by Western blotting and real-time polymerase chain reaction, respectively. The migrating and invasive ability of the cancer cells were determined by wound healing and invasive assays. Results. The IC50 value of EXD on OVCA429 cells was determined after 24 hours incubation with EXD at 1 mg/mL. EXD (1.5 mg/mL) mediated S-phase cell cycle arrest and apoptotic cell death at 24 hours posttreatment. EXD repressed the expression of several metastatic mediators, including EGFR, ErbB2, MMP2, MMP7, MMP9, and VEGF in OVCA429 cells and xenografts at transcriptional and/or translational levels. Furthermore, EXD functionally demonstrated significant inhibition of migrating and invasive ability of OVCA429 cells. EXD suppressed tumor size in xenografts without any adverse effects on body weight. Conclusions. This is the first study that illustrates the antimetastatic property of EXD on human ovarian cancer models. This decoction merits serious consideration for further delineation of its multiple pharmacological effects, especially on hormone-related cancers, and these would be valuable for future clinical applications of EXD as an alternative regime for cancers.
Persistent Identifierhttp://hdl.handle.net/10722/195707
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChu, SMEen_US
dc.contributor.authorSze, CWen_US
dc.contributor.authorCheung, HPen_US
dc.contributor.authorLiu, Qen_US
dc.contributor.authorNg, TBen_US
dc.contributor.authorTong, Yen_US
dc.date.accessioned2014-03-07T04:32:25Z-
dc.date.available2014-03-07T04:32:25Z-
dc.date.issued2013en_US
dc.identifier.citationIntegrative Cancer Therapies, 2013, v. 12, p. 336-346en_US
dc.identifier.urihttp://hdl.handle.net/10722/195707-
dc.description.abstractObjectives. Erxian Decoction (EXD) is a well-documented Chinese medicinal formulation, which has been clinically applied for years for relieving menopausal syndromes by modulating hormonal levels indicating that EXD might also be effective in treating hormone-related tumors. This study aimed to differentially investigate the efficacy of EXD and its antimetastatic property on human ovarian cancer cells, OVCA429. Methods. The efficacy and cell cycle progression of EXD on OVCA429 cells was determined by MTT assay and flow cytometry, respectively. The modulated expression of metastatic markers by EXD in OVCA429 cells and xenografts was evaluated at transcriptional and translational levels by Western blotting and real-time polymerase chain reaction, respectively. The migrating and invasive ability of the cancer cells were determined by wound healing and invasive assays. Results. The IC50 value of EXD on OVCA429 cells was determined after 24 hours incubation with EXD at 1 mg/mL. EXD (1.5 mg/mL) mediated S-phase cell cycle arrest and apoptotic cell death at 24 hours posttreatment. EXD repressed the expression of several metastatic mediators, including EGFR, ErbB2, MMP2, MMP7, MMP9, and VEGF in OVCA429 cells and xenografts at transcriptional and/or translational levels. Furthermore, EXD functionally demonstrated significant inhibition of migrating and invasive ability of OVCA429 cells. EXD suppressed tumor size in xenografts without any adverse effects on body weight. Conclusions. This is the first study that illustrates the antimetastatic property of EXD on human ovarian cancer models. This decoction merits serious consideration for further delineation of its multiple pharmacological effects, especially on hormone-related cancers, and these would be valuable for future clinical applications of EXD as an alternative regime for cancers.en_US
dc.languageengen_US
dc.publisherSAGE Journals. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510en_US
dc.relation.ispartofIntegrative Cancer Therapiesen_US
dc.titleAn In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Modelsen_US
dc.typeArticleen_US
dc.identifier.emailChu, SME: elliecsm@hku.hken_US
dc.identifier.emailSze, CW: stephens@hku.hken_US
dc.identifier.emailTong, Y: tongyao@hku.hken_US
dc.identifier.authoritySze, CW=rp00514en_US
dc.identifier.authorityTong, Y=rp00509en_US
dc.identifier.doi10.1177/1534735412464519en_US
dc.identifier.pmid23241639-
dc.identifier.hkuros228207en_US
dc.identifier.volume12en_US
dc.identifier.spage336en_US
dc.identifier.epage346en_US
dc.identifier.isiWOS:000320304400007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats